Skip to main content

Table 1 Clinical characteristics of patients n=215

From: Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?

  Female N = 64 Male N = 151 Total N = 215
Age [years] 44 (11) 50 (12) 48 (12)
Disease duration [years] 13 (8.9) 15 (8.9) 14 (8.9)
HIV infection transmission risk group
 Heterosexuals 89% (54) 27% (41) 45% (95)
 MSM 0% (0) 59% (88) 42% (88)
 Injecting drug users 8% (5) 11% (16) 10% (21)
 Others 3% (2) 3% (5) 3% (7)
Duration of ART [years] 10 (7.3) 11 (7.0) 11 (7.0)
CDC clinical stage
 A 60% (35) 66% (80) 64% (115)
 B 12% (7) 7% (9) 9% (16)
 C 28% (16) 26% (31) 26% (47)
HIV viral load below detection limit 89% (56) 93% (138) 92% (194)
CD4 [cell count/mm] 631(286) 672 (296) 661 (286)
Co-morbidities
Chronic hepatitis B (AgHbs+) 8% (5) 3% (5) 5% (10)
Hepatitis C (positive HCV serology) 12% (8) 15% (22) 14% (30)
HBV + HCV 2% (1) 1% (2) 1% (3)
Treated Diabetes 3% (2) 9% (13) 7% (15)
Treated Hypertension 20% (13) 30% (45) 27% (58)
Cancer 6% (4) 9% (13) 8% (17)
Vaccination coverage
HBV vaccination:
 up to date 64% (38) 80% (116) 75% (154)
 not up to date 20% (12) 9% (13) 12% (25)
 don’t know 15% (9) 11% (16) 12% (25)
Diphtheria-tetanus-inactivated poliovirus vaccination dTp:
 up to date 67% (43) 75% (113) 73% (156)
 not up to date 14% (9) 14% (21) 14% (30)
 don’t know 19% (12) 11% (16) 13% (28)
Pneumococcal vaccination:
 updated 16% (10) 15% (22) 15% (32)
 not up to date 62% (40) 70% (101) 67% (141)
 don’t know 22% (14) 15% (22) 17% (36)
Influenza vaccination:
 up to date 19% (12) 23% (32) 21% (44)
 not up to date 72% (46) 69% (98) 70% (144)
 don’t know 9% (6) 8% (12) 9% (18)
  1. Numerical variables are summarized using mean (SD); categorical variables are summarized using proportions (counts); MSM, men who have sex with men
\